NIH to Grant Exclusive License for Ghrelin-Based Inflammatory Disease Treatment

Summary

The National Institutes of Health is considering granting an exclusive license to Sapphire Therapeutics, Inc. to develop and commercialize a treatment for inflammatory diseases using ghrelin, as outlined in a U.S. provisional patent application filed in 2004.